BioAtla (BCAB) Free Cash Flow (2020 - 2026)
BioAtla (BCAB) posted quarterly Free Cash Flow of -$5.3 million for Q1 2026, up 67.66% year-over-year from -$3.1 million in Q1 2025, and up 33.46% quarter-over-quarter from -$7.9 million in Q4 2025.
BioAtla (BCAB) Free Cash Flow (2020 - 2026) Analysis & Trends
BioAtla's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$5.3 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 67.66% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at -$37.2 million (up 35.22% YoY), while the FY2025 annual figure was -$48.2 million, up 32.99% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$5.3 million, up from -$7.9 million in the prior quarter.
- The five-year high for Free Cash Flow was -$5.1 million in Q3 2024, with the low at -$30.8 million in Q1 2024.
- The 5-year median for Free Cash Flow is -$19.2 million (2024), against an average of -$18.8 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 81.25% in 2024, then tumbled 92.54% in 2025.
- BioAtla's Free Cash Flow stood at -$24.6 million in 2022, then decreased by 21.6% to -$29.9 million in 2023, then jumped by 43.93% to -$16.8 million in 2024, then jumped by 52.84% to -$7.9 million in 2025, then soared by 33.46% to -$5.3 million in 2026.
- Business Quant data shows BCAB's Free Cash Flow at -$5.3 million in Q1 2026, -$7.9 million in Q4 2025, and -$9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 292.04 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -95.09 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 477.44 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 433.84 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | -419,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -419,000.00 |
| Jun 30, 2026 | -419,000.00 |
| Mar 31, 2026 | -5.27 Mn |
| Mar 31, 2026 | -5.27 Mn |
| Dec 31, 2025 | -7.92 Mn |
| Dec 31, 2025 | -7.92 Mn |
| Sep 30, 2025 | -9.88 Mn |
| Sep 30, 2025 | -9.88 Mn |
| Jun 30, 2025 | -14.12 Mn |
| Jun 30, 2025 | -14.12 Mn |
| Mar 31, 2025 | -16.29 Mn |
| Mar 31, 2025 | -16.29 Mn |
| Dec 31, 2024 | -16.78 Mn |
| Dec 31, 2024 | -16.78 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Jun 30, 2024 | -19.19 Mn |
| Jun 30, 2024 | -19.19 Mn |
| Mar 31, 2024 | -30.83 Mn |
| Mar 31, 2024 | -30.83 Mn |